Results of SWOG S1826 Study, showing Nivo-AVD better than BV-AVD in Hodgkin's Lymphoma patients

Results of SWOG S1826 Study, showing Nivo-AVD better than BV-AVD in Hodgkin's Lymphoma patientsПодробнее

Polatuzumab FDA Approval in DLBCL (POLARIX) & SWOG S1826 Nivo vs. BV in Hodgkin's LymphomaПодробнее

SWOG S1826: promising results with the combination of nivolumab-AVD in Hodgkin lymphomaПодробнее

Nivolumab-AVD improved PFS versus brentuximab vedotin-AVD in patients with advanced stage HLПодробнее

Promising results from the SWOG S1826 trial: nivo-AVD versus BV-AVD in patients with cHLПодробнее

ASCO23 - LBA4: SWOG S1826, Nivolumab(N)-AVD vs. Brentuximab Vedotin(BV)-AVD in Advanced Stage (A...Подробнее